相似文献
1
The role of growth factors as a therapeutic approach to demyelinating disease.
Exp Neurol. 2016 Sep;283(Pt B):531-40. doi: 10.1016/j.expneurol.2016.02.023. Epub 2016 Mar 22.
2
Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions.
Glia. 2015 Oct;63(10):1714-28. doi: 10.1002/glia.22838. Epub 2015 Apr 22.
3
Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model.
Neurochem Res. 2007 Apr-May;32(4-5):783-97. doi: 10.1007/s11064-006-9208-6. Epub 2006 Dec 21.
4
Thymosin beta4 promotes oligodendrogenesis in the demyelinating central nervous system.
Neurobiol Dis. 2016 Apr;88:85-95. doi: 10.1016/j.nbd.2016.01.010. Epub 2016 Jan 12.
5
Functional Effects of Cuprizone-Induced Demyelination in the Presence of the mTOR-Inhibitor Rapamycin.
Neuroscience. 2019 May 15;406:667-683. doi: 10.1016/j.neuroscience.2019.01.038. Epub 2019 Jan 29.
6
Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination.
Mol Cell Neurosci. 2004 Feb;25(2):252-62. doi: 10.1016/j.mcn.2003.10.014.
7
The K -channel TASK1 affects Oligodendroglial differentiation but not myelin restoration.
Glia. 2019 May;67(5):870-883. doi: 10.1002/glia.23577. Epub 2019 Jan 9.
8
miR-219 attenuates demyelination in cuprizone-induced demyelinated mice by regulating monocarboxylate transporter 1.
Eur J Neurosci. 2017 Jan;45(2):249-259. doi: 10.1111/ejn.13485.
9
Kappa opioid receptor and oligodendrocyte remyelination.
Vitam Horm. 2019;111:281-297. doi: 10.1016/bs.vh.2019.05.004. Epub 2019 Jun 28.
10
Intranasal HB-EGF administration favors adult SVZ cell mobilization to demyelinated lesions in mouse corpus callosum.
Dev Neurobiol. 2008 Feb 1;68(2):223-36. doi: 10.1002/dneu.20588.
引用本文的文献
1
The Therapeutic Use and Potential of MSCs: Advances in Regenerative Medicine.
Int J Mol Sci. 2025 Mar 27;26(7):3084. doi: 10.3390/ijms26073084.
2
Research trends and hotspots of neuropathic pain in neurodegenerative diseases: a bibliometric analysis.
Front Immunol. 2023 Jul 12;14:1182411. doi: 10.3389/fimmu.2023.1182411. eCollection 2023.
3
The Role of BDNF in Multiple Sclerosis Neuroinflammation.
Int J Mol Sci. 2023 May 8;24(9):8447. doi: 10.3390/ijms24098447.
4
FGF/FGFR system in the central nervous system demyelinating disease: Recent progress and implications for multiple sclerosis.
CNS Neurosci Ther. 2023 Jun;29(6):1497-1511. doi: 10.1111/cns.14176. Epub 2023 Mar 16.
5
A Unique Multiplex ELISA to Profile Growth Factors and Cytokines in Cerebrospinal Fluid.
Methods Mol Biol. 2023;2612:157-168. doi: 10.1007/978-1-0716-2903-1_12.
6
A Brief Overview on BDNF-Trk Pathway in the Nervous System: A Potential Biomarker or Possible Target in Treatment of Multiple Sclerosis?
Front Neurol. 2022 Jul 12;13:917527. doi: 10.3389/fneur.2022.917527. eCollection 2022.
7
Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.
Biomedicines. 2022 Mar 30;10(4):815. doi: 10.3390/biomedicines10040815.
8
Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.
PLoS One. 2022 Mar 3;17(3):e0264557. doi: 10.1371/journal.pone.0264557. eCollection 2022.
9
New developments in the biology of fibroblast growth factors.
WIREs Mech Dis. 2022 Jul;14(4):e1549. doi: 10.1002/wsbm.1549. Epub 2022 Feb 9.
10
Neuroinductive properties of mGDNF depend on the producer, E. Coli or human cells.
PLoS One. 2021 Oct 11;16(10):e0258289. doi: 10.1371/journal.pone.0258289. eCollection 2021.
本文引用的文献
1
Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos.
Int J Mol Sci. 2016 Jan 30;17(2):185. doi: 10.3390/ijms17020185.
2
Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.
Mol Neurobiol. 2017 Mar;54(2):1046-1077. doi: 10.1007/s12035-015-9672-6. Epub 2016 Jan 22.
3
Fibroblast Growth Factor-2 Enhanced The Recruitment of Progenitor Cells and Myelin Repair in Experimental Demyelination of Rat Hippocampal Formations.
Cell J. 2015 Fall;17(3):540-456. doi: 10.22074/cellj.2015.14. Epub 2015 Oct 7.
4
Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models.
Sci Rep. 2015 Oct 14;5:15032. doi: 10.1038/srep15032.
5
Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders.
Semin Cell Dev Biol. 2016 May;53:136-43. doi: 10.1016/j.semcdb.2015.10.003. Epub 2015 Oct 23.
6
Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.
JAMA Neurol. 2015 Oct;72(10):1139-47. doi: 10.1001/jamaneurol.2015.1807.
7
Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.
Neuropharmacology. 2016 Nov;110(Pt B):605-625. doi: 10.1016/j.neuropharm.2015.06.008. Epub 2015 Jun 24.
8
Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions.
Glia. 2015 Oct;63(10):1714-28. doi: 10.1002/glia.22838. Epub 2015 Apr 22.
9
Beneficial effects of bone marrow-derived mesenchymal stem cell transplantation in a non-immune model of demyelination.
Ann Anat. 2015 Mar;198:11-20. doi: 10.1016/j.aanat.2014.12.002. Epub 2015 Jan 20.
10
Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of multiple sclerosis.
Cell Immunol. 2015 Feb;293(2):113-21. doi: 10.1016/j.cellimm.2015.01.002. Epub 2015 Jan 10.
Zotero 插件